Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares.

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Researchers analysed data from a multicenter cohort study, comparing about 1,400 COPD patients living below 1,000 feet with approximately 300 residing above 4,000 feet, mainly in cities like ...

Investors and market watchers are likely to monitor Verona Pharma's progress closely, as the company advances with its promising COPD treatment and capitalizes on its robust financial standing to ...